Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma

Drug Delivery and Translational Research

Volumn 1, Issue 4, 2011, Pages 277-288

  Tagami, Tatsuaki ^a,b   Suzuki, Takuya ^a   Hirose, Kiyomi ^a   Barichello, Jose Mario ^a,c,e   Yamazaki, Naoshi ^a   Asai, Tomohiro ^d   Oku, Naoto ^d   Ishida, Tatsuhiro ^a   Kiwada, Hiroshi ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b ONTARIO INSTITUTE FOR CANCER RESEARCH   (Canada)

^c Japan Association for the Advancement of Medical Equipment   (Japan)

^d UNIVERSITY OF SHIZUOKA   (Japan)

^e FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

Author keywords

Argonaute2 (Ago2); Cationic liposome; Fibrosarcoma; RNA interference (RNAi); Small interfering RNA (siRNA)

Indexed keywords

ARGONAUTE 2 PROTEIN; LIPOSOME; MESSENGER RNA; MICRORNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CELL ADHESION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL GROWTH; CELL STRUCTURE; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG TARGETING; FIBROSARCOMA; G1 PHASE CELL CYCLE CHECKPOINT; GENE REPRESSION; GENE SILENCING; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MALE; METABOLISM; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA INTERFERENCE; STRESS FIBER; TUMOR XENOGRAFT;

EID: 84655170679     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-011-0025-3     Document Type: Article

References (50)

1. Taconis WK, van Rijssel TG. Fibrosarcoma of long bones. A study of the significance of areas of malignant fibrous histiocytoma. J Bone Joint Surg Br. 1985; 67(1): 111-6.
2. Mocellin S, Rossi CR, Brandes A, Nitti D. Adult soft tissue sarcomas: conventional therapies and molecularly targeted approaches. Cancer Treat Rev. 2006; 32(1): 9-27.
3. Meister G, Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature. 2004; 431(7006): 343-9.
4. Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest. 2007; 117(12): 3623-32.
5. Huang C, Li M, Chen C, Yao Q. Small interfering RNA therapy in cancer: mechanism, potential targets, and clinical applications. Expert Opin Ther Targets. 2008; 12(5): 637-45.
6. Saxena N, Lahiri SS, Hambarde S, Tripathi RP. RAS: target for cancer therapy. Cancer Investig. 2008; 26(9): 948-55.
7. Pelengaris S, Khan M. The c-MYC oncoprotein as a treatment target in cancer and other disorders of cell growth. Expert Opin Ther Targets. 2003; 7(5): 623-42.
8. Aigner A. Applications of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol. 2007; 76(1): 9-21.
9. Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res. 2004; 64(10): 3365-70.
10. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006; 33(4): 369-85.
11. Kargiotis O, Chetty C, Gondi CS, Tsung AJ, Dinh DH, Gujrati M, et al. Adenovirus-mediated transfer of siRNA against MMP-2 mRNA results in impaired invasion and tumor-induced angiogenesis, induces apoptosis in vitro and inhibits tumor growth in vivo in glioblastoma. Oncogene. 2008; 27(35): 4830-40.
12. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009; 35(7): 553-62.
13. Sonoke S, Ueda T, Fujiwara K, Sato Y, Takagaki K, Hirabayashi K, et al. Tumor regression in mice by delivery of Bcl-2 small interfering RNA with pegylated cationic liposomes. Cancer Res. 2008; 68(21): 8843-51.
14. Zhang Y, Wang Y, Gao W, Zhang R, Han X, Jia M, et al. Transfer of siRNA against XIAP induces apoptosis and reduces tumor cells growth potential in human breast cancer in vitro and in vivo. Breast Cancer Res Treat. 2006; 96(3): 267-77.
15. Stege A, Priebsch A, Nieth C, Lage H. Stable and complete overcoming of MDR1/P-glycoprotein-mediated multidrug resistance in human gastric carcinoma cells by RNA interference. Cancer Gene Ther. 2004; 11(11): 699-706.
16. Degenhardt Y, Lampkin T. Targeting Polo-like kinase in cancer therapy. Clin Cancer Res. 2010; 16(2): 384-9.
17. Scholl C, Frohling S, Dunn IF, Schinzel AC, Barbie DA, Kim SY, et al. Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell. 2009; 137(5): 821-34.
18. Tokatlian T, Segura T. siRNA applications in nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2010; 2(3): 305-15.
19. Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006; 17(3): 189-202.
20. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281-97.
21. Nilsen TW. Mechanisms of microRNA-mediated gene regulation in animal cells. Trends Genet. 2007; 23(5): 243-9.
22. Cho WC. OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007; 6: 60.
23. Liu J, Carmell MA, Rivas FV, Marsden CG, Thomson JM, Song JJ, et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science. 2004; 305(5689): 1437-41.
24. Sasaki T, Shiohama A, Minoshima S, Shimizu N. Identification of eight members of the Argonaute family in the human genome small star, filled. Genomics. 2003; 82(3): 323-30.
25. Meister G, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 2004; 15(2): 185-97.
26. O'Carroll D, Mecklenbrauker I, Das PP, Santana A, Koenig U, Enright AJ, et al. A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev. 2007; 21(16): 1999-2004.
27. Tagami T, Barichello JM, Kikuchi H, Ishida T, Kiwada H. The gene-silencing effect of siRNA in cationic lipoplexes is enhanced by incorporating pDNA in the complex. Int J Pharm. 2007; 333(1-2): 62-9.
28. Barichello JM, Ishida T, Kiwada H. Complexation of siRNA and pDNA with cationic liposomes: the important aspects in lipoplex preparation. Meth Mol Biol. 2010; 605: 461-72.
29. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 2008; 26(4): 431-42.
30. Gonzalez R, Hutchins L, Nemunaitis J, Atkins M, Schwarzenberger PO. Phase 2 trial of Allovectin-7 in advanced metastatic melanoma. Melanoma Res. 2006; 16(6): 521-6.
31. Dow S, Elmslie R, Kurzman I, MacEwen G, Pericle F, Liggitt D. Phase I study of liposome-DNA complexes encoding the interleukin-2 gene in dogs with osteosarcoma lung metastases. Hum Gene Ther. 2005; 16(8): 937-46.
32. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature. 2001; 411(6836): 494-8.
33. Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, et al. Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. Biochem Biophys Res Commun. 2008; 368(2): 243-8.
34. Kobayashi T, Ishida T, Okada Y, Ise S, Harashima H, Kiwada H. Effect of transferrin receptor-targeted liposomal doxorubicin in P-glycoprotein-mediated drug resistant tumor cells. Int J Pharm. 2007; 329(1-2): 94-102.
35. Plattner R, Gupta S, Khosravi-Far R, Sato KY, Perucho M, Der CJ, et al. Differential contribution of the ERK and JNK mitogen-activated protein kinase cascades to Ras transformation of HT1080 fibrosarcoma and DLD-1 colon carcinoma cells. Oncogene. 1999; 18(10): 1807-17.
36. Tagami T, Hirose K, Barichello JM, Ishida T, Kiwada H. Global gene expression profiling in cultured cells is strongly influenced by treatment with siRNA-cationic liposome complexes. Pharm Res. 2008; 25(11): 2497-504.
37. Abu Lila AS, Kizuki S, Doi Y, Suzuki T, Ishida T, Kiwada H. Oxaliplatin encapsulated in PEG-coated cationic liposomes induces significant tumor growth suppression via a dual-targeting approach in a murine solid tumor model. J Control Release. 2009; 137(1): 8-14.
38. Nguyen LT, Atobe K, Barichello JM, Ishida T, Kiwada H. Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. Biol Pharm Bull. 2007; 30(4): 751-7.
39. Adams BD, Claffey KP, White BA. Argonaute-2 expression is regulated by epidermal growth factor receptor and mitogen-activated protein kinase signaling and correlates with a transformed phenotype in breast cancer cells. Endocrinology. 2009; 150(1): 14-23.
40. Fawcett J, Harris AL. Cell adhesion molecules and cancer. Curr Opin Oncol. 1992; 4(1): 142-8.
41. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science. 2001; 293(5536): 1829-32.
42. Jaattela M. Multiple cell death pathways as regulators of tumour initiation and progression. Oncogene. 2004; 23(16): 2746-56.
43. Gupta S. Molecular signaling in death receptor and mitochondrial pathways of apoptosis (review). Int J Oncol. 2003; 22(1): 15-20.
44. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature. 1993; 366(6456): 701-4.
45. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell. 1994; 78(1): 67-74.
46. Dimova DK, Dyson NJ. The E2F transcriptional network: old acquaintances with new faces. Oncogene. 2005; 24(17): 2810-26.
47. -/- fibrosarcomas is associated with elevated levels of cyclin kinase inhibitors p21 and p27. Mol Cell Biol. 2005; 25(11): 4565-78.
48. Abukhdeir AM, Park BH. P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008; 10: e19.
49. Antonacopoulou AG, Palli M, Marousi S, Dimitrakopoulos FI, Kyriakopoulou U, Tsamandas AC, et al. Prion protein expression and the M129V polymorphism of the PRNP gene in patients with colorectal cancer. Mol Carcinog. 2010; 49(7): 693-9.
50. Liang J, Pan Y, Zhang D, Guo C, Shi Y, Wang J, et al. Cellular prion protein promotes proliferation and G1/S transition of human gastric cancer cells SGC7901 and AGS. FASEB J. 2007; 21(9): 2247-56.